Facebook
Twitter
Telegram
Report an ErrorAIM ImmunoTech Balance Sheet 2011-2024 | AIM
Annual Balance Sheet AIM ImmunoTech
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-26.2 M | -31.9 M | -38.5 K | 4.91 M | 5.63 M | 423 K | -2.41 M | -2.11 M | -2.13 M | -747 K | -2.11 M | -1.03 M |
Long Term Debt |
659 K | 112 K | - | 3.91 M | - | 1.84 M | - | - | - | - | - | 380 K |
Long Term Debt Current |
178 K | 37 K | 47 K | 38 K | 199 K | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 6.18 M | 3.38 M | 2.8 M | 940 K | - | - | 37 K | 350 K | 479 K |
Total Current Liabilities |
1.36 M | 673 K | 1.1 M | 1.13 M | 5.29 M | 2.71 M | 2.44 M | 2.43 M | 4.44 M | 2.53 M | 12.6 M | 5.07 M |
Total Liabilities |
- | - | 3.29 K | 7.31 M | 8.67 M | 5.5 M | 3.38 M | 2.43 M | 4.44 M | 2.57 M | 13 M | 5.55 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-381 M | -361 M | - | -328 M | -319 M | -309 M | -301 M | -293 M | -278 M | -260 M | -244 M | -227 M |
Total Assets |
40.5 M | 57.7 M | 64.6 K | 20.2 M | 13.8 M | 14.2 M | 18.9 M | 22.8 M | 29.4 M | 31.9 M | 57.7 M | 43.5 M |
Cash and Cash Equivalents |
27.1 M | 32.1 M | 38.5 M | 1.47 M | 299 K | 1.41 M | 2.41 M | 2.12 M | 2.16 M | 803 K | 2.21 M | 3.1 M |
Book Value |
40.5 M | 57.7 M | 61.3 K | 12.9 M | 5.17 M | 8.7 M | 15.5 M | 20.4 M | 25 M | 29.3 M | 44.7 M | 38 M |
Total Shareholders Equity |
38.5 M | 56.9 M | 61.3 M | 13.4 M | 5.17 M | 8.7 M | 15.5 M | 20.4 M | 25 M | 29.3 M | 44.7 M | 38 M |
All numbers in USD currency
Quarterly Balance Sheet AIM ImmunoTech
| 2023-Q3 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
543 K | 597 K | 659 K | 695 K | 735 K | 84 K | 112 K | 108 K | 105 K | 1.82 M | 1.88 M | 1.88 M | 1.88 M | 1.88 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.32 M | 2.32 M | 2.32 M | 2.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.44 M | 4.27 M | 4.18 M | 3.02 M | 2.57 M | 2.57 M | 2.57 M | 2.57 M | 13 M | 13 M | 13 M | 13 M | 5.55 M | 5.55 M | 5.55 M | 5.55 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-397 M | -389 M | -381 M | -376 M | -370 M | -365 M | -361 M | -355 M | -351 M | -346 M | -342 M | -342 M | -342 M | -342 M | -328 M | -328 M | -328 M | -328 M | -319 M | -319 M | -319 M | -319 M | -309 M | -309 M | -309 M | -309 M | -301 M | -301 M | -301 M | -301 M | -293 M | -293 M | -293 M | -293 M | -278 M | -278 M | -278 M | -278 M | -260 M | -260 M | -260 M | -260 M | -244 M | -244 M | -244 M | -244 M | -227 M | -227 M | -227 M | -227 M |
Total Assets |
27.9 M | 33.6 M | 40.5 M | 46.3 M | 50.9 M | 54.2 M | 57.7 M | 63.1 M | 66.7 M | 74.1 M | 64.6 M | 64.6 M | 64.6 M | 64.6 M | 20.8 M | 20.2 M | 20.2 M | 20.2 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 57.7 M | 57.7 M | 57.7 M | 57.7 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M |
Cash and Cash Equivalents |
15.3 M | 21 M | 27.1 M | 29.8 M | 34.5 M | 29 M | 32.1 M | 37.3 M | 41.1 M | 48.8 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 1.47 M | 1.47 M | 1.47 M | 1.47 M | 299 K | 299 K | 299 K | 299 K | 1.41 M | 1.41 M | 1.41 M | 1.41 M | 2.41 M | 2.41 M | 2.41 M | 2.41 M | 2.12 M | 2.12 M | 2.12 M | 2.12 M | 2.16 M | 2.16 M | 2.16 M | 2.16 M | 803 K | 803 K | 803 K | 803 K | 2.21 M | 2.21 M | 2.21 M | 2.21 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M |
Book Value |
- | - | 40.5 M | 46.3 M | 50.9 M | 54.2 M | 57.7 M | 63.1 M | 66.7 M | 74.1 M | 64.6 M | 64.6 M | 64.6 M | 64.6 M | 20.8 M | 20.2 M | 20.2 M | 20.2 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 22.8 M | 22.8 M | 22.8 M | 22.8 M | 25 M | 25.2 M | 25.3 M | 26.4 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 44.7 M | 44.7 M | 44.7 M | 44.7 M | 38 M | 38 M | 38 M | 38 M |
Total Shareholders Equity |
22.6 M | 30.1 M | 38.5 M | 42.7 M | 48.8 M | 53.3 M | 56.9 M | 62 M | 65.5 M | 71 M | 61.3 M | 61.3 M | 61.3 M | 61.3 M | 13.4 M | 12.9 M | 12.9 M | 12.9 M | 5.58 M | 5.17 M | 5.17 M | 5.17 M | 8.7 M | 8.7 M | 8.7 M | 8.7 M | 15.5 M | 15.5 M | 15.5 M | 15.5 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 25 M | 26.4 M | 25 M | 25 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 44.7 M | 44.7 M | 44.7 M | 44.7 M | 38 M | 38 M | 38 M | 38 M |
All numbers in USD currency